1961 obese, non-diabetic participants lost approximately 15% of their body weight over 68 weeks with once-weekly 2.4 mg injectable Semaglutide, alongside lifestyle changes
May help reduce cravings
GLP-1 receptor activation slows gastric emptying and alters gut signaling
According to the company's refund policy, "If you are not a candidate or approved for GLP-1 medication, your subscription will be cancelled, and we will work with you to find another solution." The company also states that "if not deemed appropriate, you will be immediately refunded." What is the difference between the semaglutide and tirzepatide options
Sanyal Sanyal and colleagues conducted a randomized, double-blind, phase 2 study of retatrutide, a novel triple agonist of GIP, GLP-1 and glucagon receptors, vs
FDA approval is projected between late 2026 and early 2027